Liquid naloxone spray
The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid overdose, opioid dependence, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.
1. A nasal spray formulation comprising from about 5% to about 16% w/w naloxone or a pharmaceutically acceptable salt thereof, water and from about 0.001% to about 0.1% w/w of a chelating agent, wherein w/w denotes weight by total weight of the formulation.
2. The formulation of claim 1 , wherein the chelating agent is edetate disodium dihydrate.
3. The formulation of claim 1 , further comprising ethanol and propylene glycol.
4. The formulation of claim 3 , wherein the ethanol is at a concentration from about 2% to about 50% w/w and the propylene glycol is at a concentration from about 5% to about 10% w/w.
5. The formulation of claim 4 , wherein the ethanol is at a concentration from about 20% to about 50% w/w.
6. The formulation of claim 1 , wherein the naloxone or pharmaceutically acceptable salt thereof is at a concentration from about 7% to about 16% w/w.
7. The formulation of claim 1 , wherein the water is at a concentration from about 20% to about 95% w/w.
8. The formulation of claim 7 , wherein the water is at a concentration from about 30% to about 85% w/w.
9. A liquid spray formulation comprising from about 5% to about 16% w/w naloxone or a pharmaceutically acceptable salt thereof, from about 20% to about 50% w/w ethanol, from about 5% to about 10% w/w propylene glycol, from about 35% to about 70% w/w water, and from about 0.001% to about 0.1% w/w of a chelating agent, wherein w/w denotes weight by total weight of the formulation.
10. The formulation of claim 9 , wherein the chelating agent is at a concentration from about 0.005% to about 0.01% w/w.
11. The formulation of claim 9 , wherein the chelating agent is edetate disodium dihydrate.
12. A nasal spray formulation comprising from about 7% to about 16% w/w naloxone or a pharmaceutically acceptable salt thereof, water and from about 0.005% to about 0.01% w/w of a chelating agent, wherein w/w denotes weight by total weight of the formulation.
13. The formulation of claim 12 , wherein the chelating agent is edetate disodium dihydrate.
14. The formulation of claim 12 , wherein the water is at a concentration from about 10% to about 90% w/w.
15. The formulation of claim 12 , wherein the water is at a concentration from about 20% to about 90% w/w.
16. The formulation of claim 12 , wherein the water is at a concentration from about 35% to about 85% w/w.
17. The formulation of claim 12 , further comprising ethanol and propylene glycol.
18. The formulation of claim 17 , wherein the ethanol is at a concentration from about 2% to about 50% w/w and the propylene glycol is at a concentration from about 5% to about 10% w/w.
19. The formulation of claim 1 , wherein the water is at a concentration from about 10% to about 95% w/w.